BVS-EXPAND Trial

The Bioresorbable Vascular Scaffold in an Expanded Patient Population studies the performance of a bioresorbable vascular scaffold (BVS; Absorb, Abbott Vascular) in patients with complex coronary lesions.

Design: Prospective, single-arm

Patients: 180

Centers: Single

Countries: The Netherlands

Results: Device success per lesion was 99.2%. Percent diameter stenosis (P = .112) and acute gain (P = .109) were similar in patients with severe lesions, moderate lesions and noncalcified lesions. Patients with total occlusions did not differ from the rest in device success (P = .465), procedure success (P = .393), mean lumen diameter (P = .163) or percent diameter stenosis (P = .78). At 12 months, target lesion revascularization and target vessel revascularization were both 3.3%, definite scaffold thrombosis was 2.6% and there were three deaths.

Original Publications:
Diletti R, et al. Catheter Cardiovasc Interv. 2016;doi:10.1002/ccd.26832.

Healio/Cardiology News Coverage:
BVS-EXPAND: BVS feasible in patients with complex lesions